(Total Views: 61)
Posted On: 05/08/2025 2:56:44 PM
Post# of 107469
$CVM CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
Concluded a successful meeting with Saudi Food and Drug Authority
CEL-SCI was encouraged to apply for Conditional Approval with Breakthrough Therapy Designation based on data from its concluded Phase 3 study
Evaluating Saudi Arabia-based partnerships to potentially fund local manufacturing and launch Multikine throughout the region
VIENNA, Va., April 23, 2025--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that it met with the Saudi Food and Drug Authority (SFDA) to discuss the development of Multikine cancer immunotherapy* (Leukocyte Interleukin, Injection), the vast amount of Multikine data available to support a marketing application for its use as a treatment of head and neck cancer, and the possible pathways to a marketing application in Saudi Arabia.
https://finance.yahoo.com/news/cel-sci-file-r...00753.html
Concluded a successful meeting with Saudi Food and Drug Authority
CEL-SCI was encouraged to apply for Conditional Approval with Breakthrough Therapy Designation based on data from its concluded Phase 3 study
Evaluating Saudi Arabia-based partnerships to potentially fund local manufacturing and launch Multikine throughout the region
VIENNA, Va., April 23, 2025--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that it met with the Saudi Food and Drug Authority (SFDA) to discuss the development of Multikine cancer immunotherapy* (Leukocyte Interleukin, Injection), the vast amount of Multikine data available to support a marketing application for its use as a treatment of head and neck cancer, and the possible pathways to a marketing application in Saudi Arabia.
https://finance.yahoo.com/news/cel-sci-file-r...00753.html
(0)
(0)
